What does the name undifferentiated pleomorphic sarcoma mean?

It describes what the pathologist sees rather than where the tumour came from. "Undifferentiated" means the cells have lost any resemblance to a normal adult tissue, so they cannot be matched to fat, muscle, nerve or cartilage. "Pleomorphic" means the cells vary widely in size and shape. It is a soft tissue sarcoma, a cancer of the connective tissues rather than of an organ, and it is high grade, meaning it behaves aggressively. Older records may call it malignant fibrous histiocytoma, which is the name this diagnosis used to carry.

Is it a diagnosis of exclusion?

In effect, yes, and that is worth understanding because it explains why the diagnosis can take time. The pathologist runs a panel of stains and often genetic tests to look for the markers of specific sarcoma types. Undifferentiated pleomorphic sarcoma is what remains when those tests come back negative and no line of tissue origin can be identified. This is also why the reported number of cases has fallen over the years. As testing has improved, tumours that would once have been placed in this group are now given a specific name instead.

It is rare, and the honest answer is that nobody can put a precise figure on it. The main American cancer registry has no dedicated code for it, so researchers have had to estimate. Using three different reasonable definitions, the same study found rates ranging from 0.06 to 0.67 per 100,000 people a year, a more than tenfold spread. That range reflects genuine disagreement about where the boundaries of the diagnosis sit rather than poor counting.

What is the most important thing the surgery has to achieve?

A clear margin, meaning no tumour cells left at the cut edge. The evidence suggests that whether the margin is clear matters a great deal, while how many millimetres of clearance were achieved beyond that matters much less. In one series of 69 patients, those left with tumour at the margin had markedly higher odds of the tumour returning locally than those with more than a millimetre of clearance, whereas a margin of a millimetre or less was not significantly different from a wider one. That is why the operation is planned in detail from the scans beforehand.

What is radiotherapy for?

Local control. Its purpose is to reduce the chance of the tumour growing back where it started, and to make limb-sparing surgery possible in places where a generous margin cannot be taken because a major nerve or blood vessel is in the way. What it is not is a treatment that lengthens life. In a randomised trial with a median follow-up of nearly ten years, radiotherapy after limb-sparing surgery produced a highly significant reduction in local recurrence with no difference at all in overall survival. Knowing which of those two things it is for makes the trade-off against its side effects a much clearer decision.

What is chemotherapy for, and will I need it?

Chemotherapy has a completely different target. It is aimed at cells that may already have travelled elsewhere in the body but are too small to show on any scan, so its goal is to reduce distant spread and, if possible, improve survival. Whether it succeeds is genuinely debated. The largest single randomised trial, in 351 patients, found no survival difference whatsoever, while a meta-analysis of 18 trials and 1,953 patients found a small benefit that reached significance only when ifosfamide was combined with doxorubicin. Its own authors called the effect marginal. Whether it is right for you depends on the size and grade of the tumour, your general health and your own view of the trade-off, and it is a decision for the multidisciplinary team with you rather than for a surgeon alone.

Why is radiotherapy sometimes given before the operation instead of after?

The two orders carry different costs. Given beforehand a lower dose is used over a smaller area, but the wound is being closed through irradiated tissue, and the randomised trial that tested this found wound complications in 35% of patients treated beforehand compared with 17% treated afterwards. The hope is that this buys less long-term stiffness and scarring later. In the two-year follow-up of those same patients, moderate or worse scarring occurred in 48.2% treated afterwards versus 31.5% treated beforehand, but that difference did not reach statistical significance, so it remains a reasonable expectation rather than a proven one. It is a real trade-off, decided case by case.

Does this page cover tumours in the abdomen?

No. This page is about undifferentiated pleomorphic sarcoma in the limbs and the trunk wall, which is where it most commonly arises and where the surgery described here applies. The same diagnosis behind the abdominal wall or inside the skull is a different surgical problem, managed by different teams, and nothing here should be applied to it.

Undifferentiated pleomorphic sarcoma

Q: Are there newer treatments such as immunotherapy?

There is a genuine signal worth knowing about, and it needs to be kept in proportion. In an early-phase trial of the immunotherapy drug pembrolizumab in advanced sarcoma, undifferentiated pleomorphic sarcoma responded better than any other soft tissue subtype, with 4 of 10 patients showing a response. That was ten patients, in a single-arm trial, in advanced disease. It is a reason for research interest, not a treatment that can currently be offered for a tumour that has just been diagnosed and can be removed. Targeted drugs, of the kind used in some other cancers, do not yet exist for this diagnosis, because the genetic changes vary so much from one tumour to the next that no shared target has emerged.

The essentials

Undifferentiated pleomorphic sarcoma is a high-grade soft tissue sarcoma. The name describes what the pathologist can see, not where the tumour came from. It is the diagnosis reached when the tests cannot match the tumour to any specific tissue type.
Surgery is the treatment that removes the cancer. Everything else is added to it, and nothing else replaces it.
What the operation has to achieve is a clear margin. The evidence points to clear or not clear being the decisive question, rather than how many millimetres were achieved beyond clear.
Radiotherapy and chemotherapy have different goals, and this is the single most useful thing to understand. Radiotherapy is aimed at the place the tumour grew. Chemotherapy is aimed at the rest of the body. They are not two versions of the same treatment.
Radiotherapy reduces the chance of the tumour returning locally. It has not been shown to lengthen life. That is not a criticism of it. It is what it is for.
The benefit of chemotherapy is real but small, and honestly contested. The largest single randomised trial found none at all.
Nothing should be removed before the diagnosis is known. An undiagnosed lump taken out without a planned margin makes every later step harder.

What the diagnosis actually means

Most cancers are named after the tissue they arose from. This one is named after the fact that it cannot be.

Undifferentiated means the cells under the microscope have lost any resemblance to a normal adult tissue. They cannot be identified as fat, muscle, nerve, blood vessel or cartilage. Pleomorphic means they vary enormously in size and shape, which is itself a marker of aggressive behaviour. Put together, the name says: this is a sarcoma, it is high grade, and we cannot tell you what it started as.

Reaching that conclusion is a process of ruling things out. The pathologist runs a panel of stains, and frequently genetic tests, looking for the fingerprints of the specific sarcoma types. This diagnosis is what remains when those come back negative. That is worth knowing for two reasons. It explains why the answer can take longer than you expect, and it explains why this diagnosis is being made less often than it once was: as testing has sharpened, tumours that would once have landed in this category now get a specific name. Older records use the term malignant fibrous histiocytoma for the same thing.

It is rare. How rare is genuinely uncertain, and the reason is instructive. The main American cancer registry has no dedicated code for it, so one study estimated the rate three different ways using three reasonable definitions and got answers ranging from 0.06 to 0.67 per 100,000 people a year. A more than tenfold spread is not sloppy counting. It reflects real disagreement about where the edges of this diagnosis lie.

It arises most often in a limb or the trunk wall, and that is what this page is about. The same diagnosis behind the abdominal wall or elsewhere is a different surgical problem and is not covered here.

One further consequence of the biology matters later on this page. This is the most genetically varied of all the soft tissue sarcomas, and the changes differ so much from one tumour to the next that no shared target has emerged. That is the reason there is no targeted tablet for this diagnosis, in an era when many other cancers have one.

Getting the order right

The sequence is: scan, then biopsy, then plan, then operate.

A lump that might be a sarcoma should be imaged and biopsied before anyone attempts to remove it, and the biopsy should be arranged by the unit that would go on to treat it. The reason is practical. A lump removed without a diagnosis is removed without a planned margin, which means tumour is left behind in tissue that has now been opened up and contaminated. The definitive operation afterwards is larger, the reconstruction is bigger, and the result is worse than if the correct operation had been done first. This is the commonest avoidable problem in sarcoma surgery, and it is entirely a sequencing error rather than a surgical one.

The operation

The aim is to remove the tumour in one piece, unopened, surrounded by a cuff of normal tissue, while keeping the limb and as much of its function as possible.

Planning happens on the staging scans before the operation. The surgeon works out which structures the tumour abuts, which can be taken, which must be preserved, and what will be needed to close the wound afterwards. Where clearing the tumour properly means taking skin, muscle or a large volume of soft tissue, the reconstruction is planned at the same time, often with a plastic surgical colleague. That order matters: the plan for closing the wound follows the plan for clearing the tumour, never the other way around. How much tissue comes out should never be decided by how difficult it will be to close.

On margins, the useful evidence is a series of 69 patients followed for a mean of just over four years. Patients left with tumour at the cut edge had far higher odds of the tumour returning locally than those with more than a millimetre of clearance. A margin of a millimetre or less, on the other hand, was not significantly different from a wider one. Read carefully, that says something quite specific: clear is what counts, and the number of millimetres beyond clear counts for much less. It is a small retrospective series and the statistical uncertainty around its figures is wide, so it sets a direction rather than a rule. But it fits what is seen across soft tissue sarcoma generally.

Sometimes a genuinely clear margin cannot be taken in one direction, because a major nerve or artery the limb depends on is sitting against the tumour. The choice then is between sacrificing that structure, with the loss of function that follows, or accepting a planned close margin in that one place and treating it with radiotherapy. That decision is made deliberately, in advance, with you, rather than discovered during the operation. It is also the clearest single example of radiotherapy earning its place, which brings us to what the added treatments are for.

What the adjuvant treatments are for

This is the part most worth reading slowly, because the two main added treatments are commonly assumed to be two versions of the same thing, and they are not. They have different targets, different goals, and very different strengths of evidence behind them.

The word “adjuvant” simply means given in addition to the surgery. Given before the surgery it is called neoadjuvant. In both cases the surgery remains the treatment that removes the cancer.

Radiotherapy: aimed at the place the tumour grew

The goal of radiotherapy is local control. It is there to reduce the chance of the tumour regrowing where it started, and to make limb-sparing surgery possible in places where a wide margin cannot be taken. Nothing more than that, and nothing less.

The evidence is unusually clear for once. In a randomised trial of radiotherapy after limb-sparing surgery, with a median follow-up of 9.6 years, radiotherapy produced a highly significant reduction in local recurrence in high-grade tumours, and no difference in overall survival. The same pattern held in the low-grade group: fewer local recurrences, no survival difference. The trial also measured quality of life, and found radiotherapy left patients with measurably worse limb strength, more swelling and reduced movement, though these effects were often temporary and had little measurable impact on daily activities.

So radiotherapy protects the limb rather than lengthening the life. That is a real and worthwhile goal, particularly when the alternative to irradiating a close margin is removing a nerve the limb depends on. But it reframes the decision. You are not weighing side effects against survival. You are weighing side effects against the risk of the tumour returning in that spot, and against how much limb you would otherwise have to give up.

Chemotherapy: aimed at what cannot be seen

The goal of chemotherapy is entirely different. It targets the cells that may already have left.

A high-grade sarcoma can shed cells into the bloodstream before it is ever diagnosed. If that has happened, those deposits are far too small to appear on any scan at the time of surgery, and no operation can reach them. Chemotherapy is the only treatment aimed at them. Its goals, in order of how well they are supported, are to reduce distant recurrence, and if possible to improve survival.

Whether it achieves the second is honestly unresolved, and you should hear both halves of that.

The largest single randomised trial gave five cycles of doxorubicin and ifosfamide after surgery to 351 patients with high-grade sarcoma and compared them with patients who had surgery alone. It found no survival difference at all: five-year survival was 66.5% with chemotherapy and 67.8% without. Relapse-free survival was no better either.

Against that, a meta-analysis pooling 18 trials and 1,953 patients did find benefits: fewer local recurrences, fewer distant recurrences, and a survival advantage that reached statistical significance only when ifosfamide was combined with doxorubicin, not with doxorubicin alone. The authors’ own description of the effect was “marginal”, to be weighed against the toxicity.

Both of those are real results and they do not agree. Anyone who tells you this question is settled is overstating what is known. What can be said is that the benefit, if present, is modest rather than transformative, that it is larger for bigger and higher-grade tumours, and that it comes at a genuine cost in side effects.

There is one piece of evidence that speaks directly to this diagnosis. A trial of 287 patients with high-risk soft tissue sarcoma was built around five specific subtypes, and undifferentiated pleomorphic sarcoma was the largest group in it, 97 patients, just over a third of the trial. It compared the standard combination of epirubicin and ifosfamide against regimens tailored to each subtype. The standard combination won clearly enough that the trial was stopped early: disease-free survival at 46 months was 62% with standard chemotherapy against 38% with the tailored approach. Severe reductions in white cell count affected 86% of patients on the standard regimen, though there were no treatment-related deaths in either group.

Read that carefully too, because it answers a narrower question than it first appears to. It shows that if chemotherapy is being given for this diagnosis, the standard combination is the one to use, and that trying to be clever with subtype-specific drugs made things worse. It does not show that chemotherapy beats no chemotherapy, because every patient in that trial received some.

A third goal, in some cases

Occasionally treatment is given before surgery with a more immediate purpose: to shrink the tumour or firm up its edge so that the operation can be smaller, or so that a limb can be saved that otherwise could not be. Where that is the aim it is decided by the multidisciplinary team from the scans and the biopsy, and it changes the order of treatment rather than the plan.

Radiotherapy before or after the operation

If radiotherapy is being used, its timing is a real decision with a real trade-off, and it has been tested properly.

Given before surgery, a lower dose is used over a smaller area, but the surgeon is then closing a wound through tissue that has been irradiated. The randomised trial comparing the two orders found wound complications in 35% of patients treated beforehand against 17% treated afterwards, a difference of 18 percentage points. That is a substantial and well-established penalty.

The hope in accepting it is less long-term scarring and stiffness. The two-year follow-up of the same patients found moderate or worse scarring in 48.2% of those treated afterwards against 31.5% treated beforehand, with swelling and joint stiffness following the same pattern. But none of those differences reached statistical significance, and the paper says so plainly. So the late advantage of treating beforehand is a consistent direction and a reasonable expectation, not a proven fact. Patients who did develop significant scarring or stiffness scored worse on limb function, which is why the question matters at all.

The practical upshot is that neither order is simply better. Treating beforehand costs more wound problems early for a probable, unproven gain in suppleness later. It is decided case by case, and the size and site of the tumour weigh on it.

What is being researched

Two things are worth knowing, both kept firmly in proportion.

Immunotherapy has produced a real signal in this specific diagnosis. In an early-phase trial of pembrolizumab in advanced sarcoma, undifferentiated pleomorphic sarcoma responded better than any other soft tissue subtype: 4 of 10 patients, against none at all among the ten patients with leiomyosarcoma. That is a genuine and interesting finding, and it is ten patients, in a single-arm trial, in advanced disease. It is a reason for research, not a treatment that can be offered for a tumour that has just been found and can be removed.

Targeted drugs, the kind that block a specific molecular fault, do not exist for this diagnosis. That is not an oversight. As above, this is the most genetically varied of the soft tissue sarcomas, and no common target has emerged to aim at.

What this means for you

If you have been given this diagnosis, the things worth holding onto are these.

The operation is the treatment that removes the cancer, and what it has to achieve is a clear margin. That is why the planning happens in detail beforehand, and why the sequence of scan, biopsy, plan, operate should not be short-circuited by having a lump taken out first.

When radiotherapy and chemotherapy are discussed with you, ask which of the two goals is being aimed at, because the answer changes what you are weighing. Radiotherapy is about keeping the tumour from coming back where it was, and about saving limb function that would otherwise have to be sacrificed. It has not been shown to make people live longer, and it does have side effects, so it is worth being clear about what you are buying. Chemotherapy is about the disease you cannot see, and there the evidence is genuinely mixed: the benefit is probably real, probably modest, and not certain. That makes it a decision that should reflect your own view of the trade-off, not just a protocol.

Finally, this is a rare diagnosis, and rare diagnoses are managed best by teams that see them regularly. The decisions on this page are made by a multidisciplinary team, and the value of that is not bureaucratic. It is that the surgeon, the radiation oncologist, the medical oncologist, the radiologist and the pathologist are looking at the same scans and the same slides at the same time, and can say out loud where they disagree.